Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNK2 | Q07912 | 8/20 | 0.42 |
| ▸ | WEE1 | P30291 | 4/20 | 0.39 |
| ▸ | SRC | P12931 | 4/20 | 0.39 |
| ▸ | YES1 | P07947 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.36 |
| ▸ | MERTK | Q12866 | 3/20 | 0.35 |
| ▸ | IGF1R | P08069 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2959696 | 0.85 | TNK2 (0.58) | TNK2WEE1SRCYES1PDGFRB | |
| SCHEMBL2953623 | 0.84 | TNK2 (0.57) | TNK2SRCYES1PDGFRB | |
| SCHEMBL2956900 | 0.81 | TNK2 (0.58) | TNK2WEE1SRCCA12CA2 | |
| SCHEMBL2955137 | 0.77 | TNK2 (0.57) | TNK2WEE1SRC | |
| SCHEMBL2949395 | 0.74 | TNK2 (0.60) | TNK2WEE1SRC | |
| SCHEMBL2957977 | 0.74 | TNK2 (0.46) | TNK2SRCPDGFRBIGF1R | |
| SCHEMBL2949189 | 0.73 | TNK2 (0.46) | TNK2SRC | |
| SCHEMBL13239734 | 0.72 | TNK2 (0.78) | TNK2 | |
| SCHEMBL2952192 | 0.71 | TNK2 (0.47) | TNK2SRCIGF1R | |
| SCHEMBL2947095 | 0.69 | MERTK (0.46) | TNK2SRCMERTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7763624-B2 | Substituted pyrazolo[3,4-d]pyrimidines as ACK-1 and LCK inhibitors | AMGEN INC. (US) | 2010-07-27 | — | — | US | claimed |
| US-20070072851-A1 | Pyrazolopyridine and pyrazolopyrimidine compounds | AMGEN INC. (US) | 2007-03-29 | — | — | US | claimed |
| US-7763624-B2 | Substituted pyrazolo[3,4-d]pyrimidines as ACK-1 and LCK inhibitors | AMGEN INC. (US) | 2010-07-27 | — | — | US | disclosed |
| US-20070072851-A1 | Pyrazolopyridine and pyrazolopyrimidine compounds | AMGEN INC. (US) | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072851-A1 | Pyrazolopyridine and pyrazolopyrimidine compounds | LCK, MAP4K5, TPMT | TNK2 113/4885WEE1 771/4885SRC 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.